Molsidomine

Molsidomine
Clinical data
Trade names	Corvasal, Corvaton, Molsidain, Molsidolat, others
AHFS/Drugs.com	International Drug Names
Routes of; administration	By mouth (tablets), intravenous infusion
ATC code	C01DX12 (WHO) ;
Legal status
Legal status	In general: ℞ (Prescription only);
Pharmacokinetic data
Bioavailability	44–59%
Protein binding	3–11%
Metabolism	Hydrolysis
Metabolites	Linsidomine
Elimination half-life	1–2 hrs (linsidomine)
Excretion	>90% renal
Identifiers
	IUPAC name 1-Ethoxy-N-(3-morpholino-5-oxadiazol-3-iumyl)methanimidate;
CAS Number	25717-80-0 ;
PubChem CID	5353788;
DrugBank	DB09282;
ChemSpider	4090 ;
UNII	D46583G77X;
KEGG	D01320 ;
ChEBI	CHEBI:31861;
ChEMBL	ChEMBL1256353 ;
CompTox Dashboard (EPA)	DTXSID0045171 ;
ECHA InfoCard	100.042.902
Chemical and physical data
Formula	C9H14N4O4
Molar mass	242.235 g·mol−1
3D model (JSmol)	Interactive image;
Melting point	140 to 141 °C (284 to 286 °F)
	SMILES [O-]C(OCC)=Nc2on[n+](N1CCOCC1)c2;
	InChI InChI=1S/C9H14N4O4/c1-2-16-9(14)10-8-7-13(11-17-8)12-3-5-15-6-4-12/h7H,2-6H2,1H3 ; Key:XLFWDASMENKTKL-UHFFFAOYSA-N ;

Molsidomine (trade names Corvasal, Corvaton and many others) is an orally active, short acting vasodilating drug used to treat angina pectoris. Molsidomine is metabolized in the liver to the active metabolite linsidomine. Linsidomine is an unstable compound that releases nitric oxide (NO) upon decay as the actual vasodilating compound.^[1]

^ Rosenkranz B, Winkelmann BR, Parnham MJ (May 1996). "Clinical pharmacokinetics of molsidomine". Clinical Pharmacokinetics. 30 (5): 372–84. doi:10.2165/00003088-199630050-00004. PMID 8743336.